biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 5.2

an Open Access Journal by MDPI

DNA Damage and Radiotherapy

Guest Editor:

Dr. Fanghua Li
Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), German Cancer Consortium (DKTK), 45147 Essen, Germany

Deadline for manuscript submissions:
closed (30 September 2023)

Message from the Guest Editor

Radiotherapy (RT) is one of the most common and effective treatment strategies for cancer, which is effective for not only localized but also metastasis tumors. During RT, exposure of cells to ionizing radiation (IR) induces DNA double-strand breaks (DSBs), which are a major cause for lethal damage to the DNA of cancer cells, as well as being responsible for the induction of side effects. The risks posed by DSBs to the genome of higher eukaryotes are mitigated by a network of signaling pathways collectively termed the DNA damage response (DDR). DDR detects DSBs and coordinates a wide spectrum of cellular responses, including checkpoint activation and DSB repair. DDR signaling factors targeting to develop strategies for the better targeting of tumors, while the protection of normal tissues has become a subject of intensive research, such as the utilization and characterization of new radiation modality, the development and investigation of novel inhibitors of individual DSB repair pathways, etc. We, therefore, invite authors to submit original and review articles on these topics.

- radiotherapy
- normal tissue protection
- DNA damage response (DDR)
- radiation modality

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI